Evidence for the abundant expression of arginine 185 containing human CRF(2α) receptors and the role of position 185 for receptor-ligand selectivity

Neuropharmacology

Volumn 39, Issue 8, 2000, Pages 1368-1376

  Dautzenberg, Frank M ^a   Huber, Gerda ^a   Higelin, Jacqueline ^a   Py Lang, Gabrielle ^a   Kilpatrick, Gavin J ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Present Address: CeNeS Limited   (United Kingdom)

Author keywords

Genomic structure; Ligand binding; Receptor expression; RT PCR

Indexed keywords

ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR[9-41]; RECEPTOR SUBTYPE; SAUVAGINE; UROCORTIN; UROTENSIN I;

AMINO ACID SUBSTITUTION; AMYGDALOID NUCLEUS; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CELL CULTURE; CELL LINE; CEREBELLUM; CONTROLLED STUDY; GENE EXPRESSION; HEART; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPOTHALAMUS; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RETINA; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; TISSUE SPECIFICITY;

AMINO ACID SEQUENCE; ANIMALS; ARGININE; BASE SEQUENCE; BINDING, COMPETITIVE; BRAIN; CELL LINE; CORTICOTROPIN-RELEASING HORMONE; DNA; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION; HISTIDINE; HUMANS; LIGANDS; MEMBRANES; MOLECULAR SEQUENCE DATA; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RETINA; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; UROTENSINS;

EID: 0034059627     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(00)00044-7     Document Type: Article

References (25)

1. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. Journal of Endocrinology. 160:1999;1-12.
2. 2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology. 38:1999;441-448.
3. Dautzenberg F.M., Dietrich K., Palchaudhuri M.R., Spies J. Identification of two corticotropin-releasing factor receptors with high ligand selectivity from Xenopus laevis: unusual pharmacology of the type 1 receptor. Journal of Neurochemistry. 69:1997;1640-1649.
4. Dautzenberg F.M., Wille S., Lohmann R., Spies J. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proceedings of the National Academy of Science USA. 95:1998;4941-4945.
5. Dautzenberg F.M., Kilpatrick G.J., Wille S., Hauger R.L. The ligand selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand selective profile. Journal of Neurochemistry. 73:1999;821-829.
6. Dautzenberg F.M., Mevenkamp G., Wille S., Hauger R.L. N-Terminal splice variants of the type I PACAP receptor: isolation, characterization, and ligand binding/selectivity determinants. Journal of Neuroendocrinology. 11:1999;941-949.
7. Donaldson C., Sutton S., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J., Vaughan J.M., Vale W.W. Cloning and characterization of human urocortin. Endocrinology. 137:1996;2167-2170.
8. Dunn A.J., Berridge C.W. Physiological and behavioral responses of corticotropin releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Research Review. 15:1990;71-100.
9. Gulyas J., Rivier C., Perrin M., Koerber C., Sutton S., Corrigan A., Lahrichi S.L., Craig W., Vale W., Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proceedings of the National Academy of Science USA. 92:1995;10575-10579.
10. Hauger R.L., Dautzenberg F.M., Flaccus A., Liepold T., Spies J. Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. Journal of Neurochemistry. 68:1997;2308-2316.
11. Hauger R.L., Dautzenberg F.M. Regulation of the stress response by corticotropin-releasing factor receptors. Conn P.M., Freeman M.E. Neuroendocrinology in Physiology and Medicine. 1999;261-286 Humana Press Inc, New Jersey.
12. Kilpatrick G.J., Dautzenberg F.M., Martin G.R., Eglen R.M. G-protein coupled receptors - the splicing on the cake. Trends in Pharmacological Science. 20:1999;294-301.
13. 2γ receptor. Molecular Endocrinology. 12:1998;1077-1085.
14. Liaw C.W., Lovenberg T.W., Barry G., Oltersdorf T., Grigoriadis D.E., De Souza E.B. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology. 137:1996;72-77.
15. Liaw C.W., Grigoriadis D.E., Lovenberg T.W., De Souza E.B., Maki R.A. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Molecular Endocrinology. 11:1997;980-985.
16. Lovejoy D.A., Balment R.J. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. General and Comparative Endocrinology. 115:1999;1-22.
17. Luthin D.R., Rabinovich A.K., Bhumralkar D.R., Youngblood K.L., Bychowski R.A., Dhanoa D.S., May J.M. Synthesis and biological activity of oxo-7H- benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists. Bioorganic Medicine and Chemistry Letters. 9:1999;765-770.
18. 1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Current Pharmacy Design. 5:1999;289-315.
19. Palchaudhuri M.R., Wille S., Mevenkamp G., Spies J., Fuchs E., Dautzenberg F.M. Corticotropin-releasing factor receptor type 1 from Tupaia belangeri: cloning, functional expression and tissue distribution. European Journal of Biochemistry. 258:1998;78-84.
20. Palchaudhuri M.R., Hauger R.L., Wille S., Fuchs E., Dautzenberg F.M. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri. Journal of Neuroendocrinology. 11:1999;419-428.
21. Sakai K., Yamada M., Horiba N., Wakui M., Demura H., Suda T. The genomic organization of the human corticotropin-releasing factor type-1 receptor. Gene. 219:1998;125-130.
22. Seeburg P.H., Higuchi M., Sprengel R. RNA editing of brain glutamate receptor channels: mechanism and physiology. Brain Research Review. 26:1998;217-229.
23. Tsai-Morris C.H., Buczko E., Geng Y., Gamboa-Pinto A., Dufau M.L. The genomic structure of the rat corticotropin releasing factor receptor: a member of the class II G protein-coupled receptors. Journal of Biological Chemistry. 271:1996;14519-14525.
24. Udenfriend S., Gerber L., Nelson N. Scintillation proximity assay: a sensitive and continuous isotopic method for monitoring ligand/receptor and antigen/antibody interactions. Analytical Biochemistry. 161:1987;494-500.
25. Wille S., Sydow S., Palchaudhuri M.R., Spies J., Dautzenberg F.M. Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high affinity ligand binding. Journal of Neurochemistry. 72:1999;388-395.